Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non Operating Income (2017 - 2025)

Crinetics Pharmaceuticals has reported Non Operating Income over the past 9 years, most recently at -$41.0 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$41.0 million for Q4 2025, down 18688.07% from a year ago — trailing twelve months through Dec 2025 was -$27.7 million (down 437.33% YoY), and the annual figure for FY2025 was -$357000.0, up 31.21%.
  • Non Operating Income for Q4 2025 was -$41.0 million at Crinetics Pharmaceuticals, down from -$49000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for CRNX hit a ceiling of $13.5 million in Q2 2025 and a floor of -$41.0 million in Q4 2025.
  • Median Non Operating Income over the past 5 years was -$6000.0 (2021), compared with a mean of -$816200.0.
  • Biggest five-year swings in Non Operating Income: surged 8575.86% in 2023 and later tumbled 18688.07% in 2025.
  • Crinetics Pharmaceuticals' Non Operating Income stood at $171000.0 in 2021, then tumbled by 1475.44% to -$2.4 million in 2022, then skyrocketed by 101.7% to $40000.0 in 2023, then crashed by 645.0% to -$218000.0 in 2024, then tumbled by 18688.07% to -$41.0 million in 2025.
  • The last three reported values for Non Operating Income were -$41.0 million (Q4 2025), -$49000.0 (Q3 2025), and $13.5 million (Q2 2025) per Business Quant data.